Fixed Drug Eruption Management

Diagnosis and Assessment

The British Journal of Dermatology recommends obtaining a complete medication history covering the previous 2 months, including prescription drugs, OTC medications, and complementary/alternative therapies, when FDE is suspected 1
The American Academy of Dermatology suggests that essential history questions should include exact dates when medications were started, stopped, or dose-escalated, as well as the index date when first symptoms appeared 1
The diagnosis of FDE is primarily clinical, based on three essential historical features: recurrence at the same anatomical site, temporal relationship to drug exposure, and resolution with hyperpigmentation after drug discontinuation, as noted by the British Journal of Dermatology 1

The American College of Dermatology recommends immediate and permanent discontinuation of the causative drug as the cornerstone of FDE management, which directly impacts prognosis 2
For localized/mild FDE, the European Academy of Dermatology and Venereology suggests applying topical moderate-to-high potency corticosteroids, such as mometasone furoate 0.1% or betamethasone valerate 0.1% ointment, twice daily to affected areas 2
The Centers for Disease Control and Prevention advises that hospitalization is indicated for extensive body surface area involvement, systemic symptoms, or suspicion of progression to SJS/TEN, and that supportive care should include applying emollients, avoiding hot showers and excessive soap use, and limiting sun exposure 4
The Journal of Allergy and Clinical Immunology notes that cross-reactivity with structurally similar drugs is possible, and that patients should be educated to avoid these drugs 3

The American Academy of Dermatology recommends documenting the reaction thoroughly in the medical record to prevent future re-exposure to the causative agent, including the specific drug implicated, description of the reaction, and sites of involvement 4
The British Journal of Dermatology suggests that follow-up at 4 weeks is recommended to confirm resolution and reinforce avoidance of the causative medication, and that patients should be educated that the reaction will recur at the same sites if re-exposed to the drug 1